Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10699768 | 0.86 | DUT (0.47) | DUTMEN1KMT2ANT5EP2RY12 | |
| SCHEMBL22666246 | 0.86 | DUT (0.47) | DUTMEN1KMT2ANT5EP2RY12 | |
| SCHEMBL21376704 | 0.85 | ABL1 (0.46) | DUTMEN1KMT2AABL1RIN1 | |
| SCHEMBL21376702 | 0.85 | ABL1 (0.46) | DUTMEN1KMT2AABL1RIN1 | |
| SCHEMBL10463851 | 0.85 | ABL1 (0.46) | DUTMEN1KMT2AABL1RIN1 | |
| SCHEMBL23808328 | 0.85 | ABL1 (0.46) | DUTMEN1KMT2AABL1RIN1 | |
| SCHEMBL10465192 | 0.85 | ABL1 (0.46) | DUTMEN1KMT2AABL1RIN1 | |
| SCHEMBL22110553 | 0.82 | DUT (0.41) | DUTP2RY2P2RY6P2RY4 | |
| SCHEMBL19236112 | 0.82 | DUT (0.41) | DUTP2RY2P2RY6P2RY4 | |
| SCHEMBL10513957 | 0.81 | ABL1 (0.47) | P2RY12ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | PARP1, PARP2, CD38 | DUT 28/4885MEN1 2121/4885KMT2A 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.